Investegate |Global Blood Therapeutics, Inc Announcements | Global Blood Therapeutics, Inc: Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT's Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
Investegate announcements from Global Blood Therapeutics, Inc, Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease